Results 61 to 70 of about 5,710 (181)

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong, Zaiyong Zheng, Min Huang, Shengyu Huang, Xingwei Zhao, Yang Yu, Chunxiang Zhang   +6 more
wiley   +1 more source

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

Reviews in Cardiovascular Medicine
Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide.
Lawrence A. Leiter, Robert A. Hegele, Vivien Brown, Jean Bergeron, Erin S. Mackinnon, G. B. John Mancini   +5 more
doaj   +1 more source

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial

Trials, 2022
Background Despite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG).
Hye Rim Na, O Sung Kwon, Joon Kyu Kang, Yong Han Kim, Ju Yong Lim   +4 more
doaj   +1 more source

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis

Frontiers in Pharmacology
BackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events.
Leyu Xu, Leyu Xu, Ming Lei, Ming Lei, Liren Li, Liren Li, Yilei Li, Yilei Li, Chunping Gu, Chunping Gu, Ping Zheng, Ping Zheng   +11 more
doaj   +1 more source

DrugUtilisation: An R Package to Support Drug Utilisation Research Using the OMOP Common Data Model

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 7, July 2026.
ABSTRACT Purpose To develop and describe DrugUtilisation, an open‐source R package that facilitates drug utilisation studies using data mapped to the OMOP Common Data Model (CDM). Methods Core functionalities include creating drug user cohorts, identifying and summarising indications, describing the duration and dose of medication/s and assessing ...
Yuchen Guo, Edward Burn, Annika M. Jödicke, Núria Mercadé‐Besora, Kim Lopez‐Güell, Xihang Chen, Mike Du, Xintong Li, Raivo Kolde, Marek Oja, Mees Mosseveld, Katia Verhamme, Julieta Politi, Antonella Delmestri, Wai Yi Man, Peter Rijnbeek, Daniel Prieto‐Alhambra, Martí Català   +17 more
wiley   +1 more source

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma

Scientific Reports
Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma.
Kirit Singh, Matthew W. Foster, Marlene J. Violette, Anna M. Corcoran, Kelly M. Hotchkiss, Chelsea O. Railton, Emily E. Blandford, Kathryn E. Blethen, Elizabeth L. Thomas, William C. McIntosh, David M. Ashley, Annick Desjardins, Henry S. Friedman, Margaret O. Johnson, Allan Friedman, Stephen Keir, Evan D. Buckley, James E. Herndon, Roger E. McLendon, John H. Sampson, Evan Calabrese, Giselle Y. López, Gerald A. Grant, Anoop P. Patel, Simon G. Gregory, Chuan-Yuan Li, Peter E. Fecci, Mustafa Khasraw   +27 more
doaj   +1 more source

Isolated Gamma‐Glutamyltransferase Elevation During Statin Therapy: A Diagnostic Pitfall and a Stepwise Management Framework to Prevent Unnecessary Discontinuation

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT The management of patients with isolated gamma‐glutamyltransferase (GGT) elevation during statin therapy remains a common clinical dilemma due to the unclear relevance to hepatotoxicity. We report a case of a patient with coronary artery disease who developed persistent isolated GGT elevation (> 100 U/L) while on atorvastatin, with normal ...
Jun Yang, Yanling He, Zhengyong Zhang
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

Cost Effectiveness and Resource Allocation, 2023
Background According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease.
Yuansheng Wan, Jinyu Liu, Xiaolian Zhan, Yu Zhang, Ruxu You   +4 more
doaj   +1 more source

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia

In this report, we describe a patient with a delayed cutaneous hypersensitivity reaction to evolocumab, a human monoclonal antibody directed against the serine protease proprotein convertase subtilisin/kexin type 9 used to reduce low-density lipoprotein ...
Dziadowiec, Alicja, Grzegorz Porebski, Alicja Dziadowiec, Porębski, Grzegorz   +3 more
core   +1 more source